获取途径

作者

Hong Zheng Yunong Gao Hongyan Guo Li Li Qingshui Li Heng Cui An Lin Lixin Sun Yuanjing Hu Shan Kang Wei Duan Lingya Pan Shuzhen Wang Yingjie Yang Yunxia Li Weimin Kong Yang Xiang Xiaofei Tian Bin Ling Chunfang Ha Wenpei Bai

作者单位

Affiliations ¹ Gynecologic Oncology, The University of Texas MD Anderson Cancer Center. ² Department of Gynecology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute gaoyunong@vip.sina.com. ³ Obstetrics & Gynecology, Peking University Third Hospital. ⁴ The Third Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Cancer Hospital). ⁵ Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences. ⁶ Gynecological Oncology Center, Peking University People's Hospital. ⁷ Fujian Cancer Hospital. ⁸ Cancer Center of Shanxi Province, Shanxi. ⁹ Tianjin Central Hospital of Gynecology Obstetrics. ¹⁰ Hebei Medical University, Fourth Hospital. ¹¹ Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital. ¹² Peking Union Medical College Hospital. ¹³ Beijing Chaoyang Hospital Affiliated to Capital Medical University. ¹⁴ Guizhou Cancer Hospital. ¹⁵ General Hospital of Ningxia Medical University. ¹⁶ Department of Obstetrics and Gynecology, Peking Union Medical College Hospital. ¹⁷ Shaanxi Province Tumour Hospital. ¹⁸ Anhui Province Key Laboratory of Molecular Medicine and Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University. ¹⁹ Beijing Shijitan Hospital, Capital Medical University, Peking University Ninth School of Clinical Medicine.

刊名

Molecular cancer therapeutics

年份

2021

卷号

Vol.20 No.9

页码

1735-1742

ISSN

1535-7163

关键词

GERMLINE BRCA1/2 MUTATION MAINTENANCE THERAPY DOUBLE-BLIND CHEMOTHERAPY MONOTHERAPY RESISTANCE CARCINOMA

摘要

The objective of this study was to evaluate the real-world application, efficacy, and safety data of Olaparib for maintenance therapy and active treatment in ovarian cancer patients in China. Ovarian cancer patients from 17 institutions in China treated with Olaparib as maintenance or active therapy from January 2018 to March 2020 were included in this study. The medical records were reviewed, and follow-up information was collected for analysis of the patients' clinicopathological characteristi...更多

The objective of this study was to evaluate the real-world application, efficacy, and safety data of Olaparib for maintenance therapy and active treatment in ovarian cancer patients in China. Ovarian cancer patients from 17 institutions in China treated with Olaparib as maintenance or active therapy from January 2018 to March 2020 were included in this study. The medical records were reviewed, and follow-up information was collected for analysis of the patients' clinicopathological characteristics as well as the effectiveness and safety of Olaparib. A total of 251 patients receiving Olaparib were included, with 84 as maintenance therapy after first-line chemotherapy , 97 as maintenance therapy after platinum-sensitive recurrence , and 70 as active treatment . The probability of progression-free survival at 12 months was 87.6% in the FL-M group and 63.8% in the PSR-M group. According to the multivariate analysis, complete response to chemotherapy for the PSR-M patients was the only factor affecting the PFS , and platinum-sensitivity was the only factor affecting PFS improvement in the AT group . In the AT group, the objective response rate was 37.1%, the CR rate was 7.1%, and 30% of the patients had stable disease. Eight patients discontinued Olaparib due to toxicity. Anemia was the most common adverse event. In conclusion, Olaparib is effective and well-tolerated in the real-world setting of ovarian cancer treatment. Platinum sensitivity is positively correlated to the effectiveness of Olaparib in both maintenance and active treatment.收起

文献类型

期刊

浏览量

12